Biogen sales interviews focus on developing the LEQEMBI neurology practice relationships and diagnostic pathway capabilities that convert early Alzheimer's disease specialists from awareness to active prescribing, where the clinical account manager's job is not to close a prescription but to develop the neurologist's practice readiness including amyloid confirmation testing access, ARIA monitoring protocol familiarity, and infusion center coordination before the first patient can be initiated, defending and growing the TYSABRI formulary position at MS centers where the monthly infusion burden and JC virus monitoring requirements create patient retention challenges but where TYSABRI's efficacy profile makes it the preferred option for neurologists treating patients with active relapsing MS who are JC antibody negative, driving SPINRAZA adoption at neuromuscular disease centers where early treatment of spinal muscular atrophy infants and children with intrathecal nusinersen requires relationships with the small number of pediatric neuromuscular specialists who manage the SMA patient population, and selling SKYCLARYS to the Friedreich's ataxia specialist community where the neuromuscular disease neurologists who treat FA patients are few in number but each manages a disproportionately large share of the addressable patient population, making each physician relationship highly valuable and requiring deep scientific engagement about SKYCLARYS's mechanism and clinical evidence. The interview tests whether you understand how sales at a neurology biotech differs from sales at a diversified pharmaceutical company, a medical device firm, or a consumer health organization.

Start your free Biogen Sales practice session.

What interviewers actually evaluate

LEQEMBI Neurology Practice Development and Alzheimer's Diagnostic Pathway Enablement, TYSABRI MS Formulary Defense, SPINRAZA Neuromuscular Center Development, and SKYCLARYS Friedreich's Ataxia Specialist Engagement

Biogen sales interviews probe whether you understand the practice readiness development approach, clinical evidence selling, and rare disease specialist engagement that define sales in the specialty neurology biotech market. LEQEMBI clinical account management requires understanding that the initial commercial challenge is not prescriber resistance to a new Alzheimer's therapy but rather the systematic underdevelopment of the diagnostic and treatment infrastructure that prevents interested neurologists from initiating their first LEQEMBI patient. TYSABRI MS sales requires understanding how to maintain neurologist confidence in TYSABRI's benefit-risk profile for carefully selected patients in a competitive environment where newer MS therapies offer more convenient administration.

What gets scored in every session

Specific, sentence-level feedback.

Dimension What it measures How to answer
LEQEMBI neurology practice development and Alzheimer's diagnostic pathway enablement Do you understand how Biogen's LEQEMBI clinical account managers develop the neurologist practice readiness that must precede LEQEMBI prescribing, including how you assess each practice's current diagnostic pathway capabilities, identify the specific barriers that are preventing the practice from initiating LEQEMBI patients, and develop the customized practice development plan that resolves each barrier? Describe how you would develop the LEQEMBI practice readiness program for a community neurology practice with three neurologists who see approximately 50 early Alzheimer's patients per year and who are interested in LEQEMBI but have not initiated any patients because they have not yet established an amyloid testing pathway and are uncertain about the ARIA monitoring protocol, including how you assess the practice's current cognitive evaluation and dementia workup workflow to identify where amyloid confirmation testing would fit in the diagnostic sequence and which specific tests, amyloid PET or CSF biomarkers, are most feasible for this practice's patient population and local testing infrastructure, how you develop the amyloid testing access solution for a practice that does not have on-site amyloid PET capability by identifying the PET scanning facilities in the practice's catchment area that are willing to perform amyloid PET for LEQEMBI evaluation purposes, how you address the ARIA monitoring concern by providing the practice with clear guidance on the MRI protocol, monitoring intervals, and ARIA management algorithm specified in LEQEMBI's labeling, and how you identify the infusion center where the practice's LEQEMBI patients can receive their biweekly infusions and coordinate the referral pathway between the neurologist and the infusion site
TYSABRI MS specialist account management and JC risk-benefit selling Can you describe how Biogen's TYSABRI sales team manages the MS specialist neurologist relationships where the clinical account manager must support the neurologist's TYSABRI prescribing by providing accurate and timely JC virus antibody risk stratification information and helping neurologists navigate the risk-benefit discussion with patients who are being evaluated for TYSABRI initiation or who are considering transitioning from TYSABRI due to rising JC antibody index values? Walk through how you would manage the TYSABRI account relationship at a large MS center where the five neurologists who previously prescribed TYSABRI for approximately 60 patients have become more conservative about TYSABRI initiation in the past year as their patients' JC antibody prevalence has risen with longer treatment duration, including how you assess the reasons for the prescribing shift including whether it reflects legitimate clinical concern about JC risk in their specific patient population, competitive pressure from Ocrevus and Kesimpta representatives who are actively presenting their own efficacy data, or operational frustration with the TOUCH program's administrative burden, how you develop the account response strategy that addresses each identified concern including presenting the updated JC antibody stratification data that allows more precise PML risk quantification for the neurologists' specific patient panel, how you position TYSABRI for the newly diagnosed active relapsing MS patients who are JC antibody negative and in whom TYSABRI's efficacy profile is most compelling, and how you manage the relationship with the neurologists who are transitioning existing JC positive TYSABRI patients to alternative therapies in a way that preserves the relationship for the TYSABRI-eligible patients they will continue to see
SPINRAZA neuromuscular center development and SMA patient identification Do you understand how Biogen's SPINRAZA sales team develops the neuromuscular disease center relationships that are essential for SPINRAZA prescribing, including how you work with pediatric neuromuscular specialists to identify the SMA patients in their practice who have not yet been initiated on SPINRAZA therapy and to develop the treatment initiation process for infants and children who require intrathecal injection in a specialized clinical setting? Explain how you would develop the SPINRAZA commercial program at a pediatric neuromuscular disease center that currently manages approximately 30 SMA patients across Type 1, Type 2, and Type 3 disease, where SPINRAZA is the approved therapy for older patients who did not receive neonatal SMA screening or who have disease severity or genotype that makes them candidates for SPINRAZA rather than competing SMA gene therapy, including how you assess which patients in the center's current SMA population have not been initiated on any disease-modifying therapy and are potentially appropriate SPINRAZA candidates based on their age, SMA type, and treatment history, how you develop the physician engagement strategy for the center's neuromuscular specialist to discuss SPINRAZA's clinical evidence in the specific SMA subtypes represented in their patient population, how you coordinate with the hospital pharmacy and intrathecal injection team to ensure the logistical pathway for SPINRAZA preparation and administration is established before the physician's first patient is identified, and how you develop the patient services support program for the families who need insurance authorization assistance and financial support for SPINRAZA's high treatment cost
SKYCLARYS Friedreich's ataxia specialist commercial engagement Can you describe how Biogen's SKYCLARYS commercial team engages the small community of neuromuscular disease neurologists who treat Friedreich's ataxia patients, including how you develop the scientific credibility and clinical relationship with each FA specialist that is necessary for them to confidently prescribe SKYCLARYS as the first approved disease-modifying therapy for their FA patients? Describe how you would develop the SKYCLARYS commercial engagement program for the Friedreich's ataxia specialist community in a region where three neuromuscular disease neurologists at academic medical centers together manage approximately 75 FA patients, including how you assess each neurologist's current knowledge of SKYCLARYS's mechanism of action as an NRF2 activator that addresses oxidative stress in FA, the clinical trial evidence from the MOXIe study that supported SKYCLARYS's approval, and the practical aspects of prescribing SKYCLARYS including the titration schedule and the monitoring for hepatotoxicity that is included in SKYCLARYS's labeling, how you develop the scientific engagement strategy that deepens each neurologist's understanding of SKYCLARYS's clinical profile in a peer-level scientific conversation rather than a promotional presentation, how you identify within each neurologist's patient panel the FA patients who meet SKYCLARYS's indication for patients 16 years of age and older and who have not yet been initiated on SKYCLARYS, and how you develop the patient services support program that helps FA patients and families navigate insurance prior authorization for SKYCLARYS and access Biogen's financial assistance programs

How a session works

Step 1: Choose a Biogen sales scenario: LEQEMBI practice readiness development for a community neurology practice with diagnostic pathway barriers, TYSABRI account management for a large MS center where JC risk concern is reducing TYSABRI initiation, SPINRAZA neuromuscular center development with SMA patient identification and intrathecal pathway coordination, or SKYCLARYS Friedreich's ataxia specialist scientific engagement and patient identification.

Step 2: The AI interviewer asks realistic neurology biotech sales questions: how you would identify and resolve the specific LEQEMBI diagnostic pathway barrier that is preventing a community neurologist from initiating their first patient, how you would address a TYSABRI-prescribing neurologist's concern about rising JC antibody prevalence in their patient panel, or how you would assess which patients in a neuromuscular center's SMA population are candidates for SPINRAZA versus competing SMA therapies.

Step 3: You respond as you would in the actual interview. The system scores your answer on clinical practice development specificity, competitive selling depth, and rare disease specialist engagement quality.

Step 4: You get sentence-level feedback on what demonstrated genuine neurology biotech sales expertise and what needs stronger Alzheimer's diagnostic pathway knowledge or TYSABRI JC risk stratification specificity.

Frequently Asked Questions

Why is LEQEMBI's commercial challenge primarily a practice development problem rather than a prescriber persuasion problem?
LEQEMBI's early commercial experience has demonstrated that the primary constraint on patient initiation is not neurologist skepticism about LEQEMBI's clinical value, but rather the systematic underdevelopment of the clinical infrastructure required to evaluate, initiate, and monitor LEQEMBI patients. Many neurologists who are interested in prescribing LEQEMBI for appropriate early Alzheimer's patients have not initiated their first patient because they have not yet established access to amyloid confirmation testing, identified a suitable infusion site for biweekly administration, or developed comfort with the ARIA monitoring protocol. Clinical account managers who focus on these practice readiness barriers, developing amyloid testing referral pathways, connecting neurologists with infusion centers, and providing ARIA monitoring guidance, unlock prescribing capability more effectively than account managers who spend their time presenting clinical evidence to neurologists who already understand and believe in LEQEMBI's value.

How does TYSABRI's JC virus monitoring affect the sales conversation?
TYSABRI's JC virus antibody monitoring program is central to every TYSABRI clinical conversation because the PML risk associated with TYSABRI treatment is stratified based on JC antibody status and treatment duration. Neurologists who prescribe TYSABRI must communicate JC antibody test results to their patients and engage in ongoing risk-benefit discussions as patients' JC antibody status changes over time. Biogen's clinical account managers support these conversations by providing neurologists with accurate JC antibody risk stratification data, the PML risk calculation tools that translate JC antibody index values and treatment duration into PML risk estimates, and the updated published literature on PML risk reduction strategies including extended dosing interval protocols that some neurologists use to reduce PML risk while maintaining therapeutic benefit. These clinical support activities differentiate Biogen's account management from a transactional sales approach and build the neurologist trust that sustains TYSABRI prescribing.

What competitive dynamics affect SPINRAZA's commercial position?
SPINRAZA faces competition from two gene therapy alternatives for SMA, Novartis's Zolgensma for SMA patients under two years of age and AstraZeneca's Risdiplam (Evrysdi) for patients of multiple ages who prefer an oral treatment. Zolgensma's one-time IV administration versus SPINRAZA's four initial intrathecal injections and then quarterly maintenance injections creates a significant administration convenience advantage for younger patients where Zolgensma is approved. Risdiplam's oral administration eliminates the intrathecal injection requirement entirely, creating another competitive option for patients and families who want to avoid the procedural burden of intrathecal SPINRAZA. SPINRAZA's commercial position is sustained primarily in older patients who were not diagnosed in the newborn screening era and who have pre-existing SPINRAZA therapy, patients with disease severity or genotype profiles that affect the risk-benefit assessment of gene therapy versus SPINRAZA, and patient-physician pairs who prefer the established clinical evidence base and safety profile of SPINRAZA relative to the newer gene therapy and oral options.

How does selling to rare disease specialists differ from selling to broader neurology audiences?
Rare disease specialty selling, such as SKYCLARYS sales to Friedreich's ataxia specialists, involves engaging a small number of physicians who each manage disproportionately large shares of the patient population and who have deep disease expertise that typically exceeds the clinical account manager's own knowledge. In these settings, the account manager's value is not clinical education in the traditional sense but rather scientific partnership, connecting the specialist with the latest SKYCLARYS real-world evidence, supporting patient access and services, and ensuring that the specialist has the clinical and commercial support needed to treat their FA patients with SKYCLARYS. The commercial opportunity is highly concentrated, with a small number of accounts representing the majority of the addressable market, making each specialist relationship high-stakes and requiring account managers with exceptional scientific depth and physician relationship skills.

What patient services support does Biogen provide for LEQEMBI patients?
Biogen and Eisai jointly operate comprehensive patient services programs for LEQEMBI that address the multiple access and support needs of Alzheimer's patients and their caregivers who are pursuing LEQEMBI therapy. These programs include insurance verification and prior authorization support that helps neurologist practices navigate the commercial insurance and Medicare coverage requirements for LEQEMBI, financial assistance programs that provide co-pay support for commercially insured patients with significant out-of-pocket cost sharing, and coordination support for the amyloid confirmation testing, infusion scheduling, and MRI monitoring activities that constitute the LEQEMBI patient journey. The patient services infrastructure is a critical component of Biogen's commercial program because the complexity of LEQEMBI's access pathway means that patients and neurologist practices who encounter access barriers without dedicated support are likely to abandon the treatment initiation process rather than persisting through the multiple steps required to reach first infusion.

Also practice

One full session free. No account required. Real, specific feedback.